Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism

Paul W Ladenson, Steven I. Sherman, Kenneth L. Baughman, Phillip E. Ray, Arthur M. Feldman

Research output: Contribution to journalArticle

Abstract

Thyroid hormone effects on myocardial gene expression have been well defined in animal models, but their relationship to the pathogenesis of cardiac dysfunction in hypothyroid humans has been uncertain. We evaluated a profoundly hypothyroid young man with dilated cardiomyopathy. Before and during 9 months of thyroxine therapy, serial assessment of myocardial performance documented substantial improvements in the left ventricular ejection fraction (16-37%), left ventricular end-diastolic diameter (7.8-5.9 cm), and cardiac index (1.4-2.7 liters-min-1·m-2). Steady-state levels of mRNAs encoding selected cardiac proteins were measured in biopsy samples obtained before and after thyroxine replacement. In comparison with myocardium from nonfailing control hearts, this patient's pretreatment α-myosin heavy-chain mRNA level was substantially lower, the atrial natriuretic factor mRNA level was markedly elevated, and the phospholamban mRNA level was decreased. All of these derangements were reversed 9 months after restoration of euthyroidism. These observations in an unusual patient with profound myxedema and cardiac dilatation permit correlation between the reversible changes in myocardial function and steady-state mRNA levels in a cardiomyopathy. They suggest that alterations in gene expression in the dilated myopathic heart may be correctable when a treatable cause is identified.

Original languageEnglish (US)
Pages (from-to)5251-5255
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume89
Issue number12
StatePublished - 1992

Fingerprint

Dilated Cardiomyopathy
Hypothyroidism
Gene Expression
Messenger RNA
Thyroxine
Myxedema
Myosin Heavy Chains
Atrial Natriuretic Factor
Cardiomyopathies
Thyroid Hormones
Stroke Volume
Dilatation
Myocardium
Animal Models
Biopsy
Proteins

Keywords

  • Heart failure
  • Myocardium

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism. / Ladenson, Paul W; Sherman, Steven I.; Baughman, Kenneth L.; Ray, Phillip E.; Feldman, Arthur M.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 89, No. 12, 1992, p. 5251-5255.

Research output: Contribution to journalArticle

@article{587f6d72c18f46d1bae4b28e5725ec44,
title = "Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism",
abstract = "Thyroid hormone effects on myocardial gene expression have been well defined in animal models, but their relationship to the pathogenesis of cardiac dysfunction in hypothyroid humans has been uncertain. We evaluated a profoundly hypothyroid young man with dilated cardiomyopathy. Before and during 9 months of thyroxine therapy, serial assessment of myocardial performance documented substantial improvements in the left ventricular ejection fraction (16-37{\%}), left ventricular end-diastolic diameter (7.8-5.9 cm), and cardiac index (1.4-2.7 liters-min-1·m-2). Steady-state levels of mRNAs encoding selected cardiac proteins were measured in biopsy samples obtained before and after thyroxine replacement. In comparison with myocardium from nonfailing control hearts, this patient's pretreatment α-myosin heavy-chain mRNA level was substantially lower, the atrial natriuretic factor mRNA level was markedly elevated, and the phospholamban mRNA level was decreased. All of these derangements were reversed 9 months after restoration of euthyroidism. These observations in an unusual patient with profound myxedema and cardiac dilatation permit correlation between the reversible changes in myocardial function and steady-state mRNA levels in a cardiomyopathy. They suggest that alterations in gene expression in the dilated myopathic heart may be correctable when a treatable cause is identified.",
keywords = "Heart failure, Myocardium",
author = "Ladenson, {Paul W} and Sherman, {Steven I.} and Baughman, {Kenneth L.} and Ray, {Phillip E.} and Feldman, {Arthur M.}",
year = "1992",
language = "English (US)",
volume = "89",
pages = "5251--5255",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "12",

}

TY - JOUR

T1 - Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism

AU - Ladenson, Paul W

AU - Sherman, Steven I.

AU - Baughman, Kenneth L.

AU - Ray, Phillip E.

AU - Feldman, Arthur M.

PY - 1992

Y1 - 1992

N2 - Thyroid hormone effects on myocardial gene expression have been well defined in animal models, but their relationship to the pathogenesis of cardiac dysfunction in hypothyroid humans has been uncertain. We evaluated a profoundly hypothyroid young man with dilated cardiomyopathy. Before and during 9 months of thyroxine therapy, serial assessment of myocardial performance documented substantial improvements in the left ventricular ejection fraction (16-37%), left ventricular end-diastolic diameter (7.8-5.9 cm), and cardiac index (1.4-2.7 liters-min-1·m-2). Steady-state levels of mRNAs encoding selected cardiac proteins were measured in biopsy samples obtained before and after thyroxine replacement. In comparison with myocardium from nonfailing control hearts, this patient's pretreatment α-myosin heavy-chain mRNA level was substantially lower, the atrial natriuretic factor mRNA level was markedly elevated, and the phospholamban mRNA level was decreased. All of these derangements were reversed 9 months after restoration of euthyroidism. These observations in an unusual patient with profound myxedema and cardiac dilatation permit correlation between the reversible changes in myocardial function and steady-state mRNA levels in a cardiomyopathy. They suggest that alterations in gene expression in the dilated myopathic heart may be correctable when a treatable cause is identified.

AB - Thyroid hormone effects on myocardial gene expression have been well defined in animal models, but their relationship to the pathogenesis of cardiac dysfunction in hypothyroid humans has been uncertain. We evaluated a profoundly hypothyroid young man with dilated cardiomyopathy. Before and during 9 months of thyroxine therapy, serial assessment of myocardial performance documented substantial improvements in the left ventricular ejection fraction (16-37%), left ventricular end-diastolic diameter (7.8-5.9 cm), and cardiac index (1.4-2.7 liters-min-1·m-2). Steady-state levels of mRNAs encoding selected cardiac proteins were measured in biopsy samples obtained before and after thyroxine replacement. In comparison with myocardium from nonfailing control hearts, this patient's pretreatment α-myosin heavy-chain mRNA level was substantially lower, the atrial natriuretic factor mRNA level was markedly elevated, and the phospholamban mRNA level was decreased. All of these derangements were reversed 9 months after restoration of euthyroidism. These observations in an unusual patient with profound myxedema and cardiac dilatation permit correlation between the reversible changes in myocardial function and steady-state mRNA levels in a cardiomyopathy. They suggest that alterations in gene expression in the dilated myopathic heart may be correctable when a treatable cause is identified.

KW - Heart failure

KW - Myocardium

UR - http://www.scopus.com/inward/record.url?scp=0026755208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026755208&partnerID=8YFLogxK

M3 - Article

C2 - 1376915

AN - SCOPUS:0026755208

VL - 89

SP - 5251

EP - 5255

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 12

ER -